{"DataElement":{"publicId":"2500916","version":"1","preferredName":"Eligibility Exclusion Criteria 03058_01 Text Name","preferredDefinition":"Text eligibility criteria (exclusion only) that are used to evaluate candidates for enrollment into Lombardi Cancer Center trial #03058, amendment 1.","longName":"ELIG_EXC_03058_01_nm","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2500913","version":"1","preferredName":"Exclusion Eligibility Criteria Text","preferredDefinition":"Text Criteria (exclusion only) that are used to evaluate candidates for enrollment into a clinical trial.","longName":"EXC_ELIG_CRIT_TXT","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2500911","version":"1","preferredName":"Exclusion Clinical Trial Eligibility Criteria","preferredDefinition":"Exclusion; the act of restricting entrance or barring from participation.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25370:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exclusion Criteria","conceptCode":"C25370","definition":"Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19E0BF0E-2659-482D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"ONEDATA","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2228365","version":"1","preferredName":"Text","preferredDefinition":"The words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6DEAE35-C96D-734E-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-11","endDate":null,"createdBy":"UMLLOADER_COMMON","dateCreated":"2005-05-11","modifiedBy":"DWARZEL","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19E0BF0E-2667-482D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2500914","version":"1","preferredName":"Eligibility Exclusion Criteria Question Text Name","preferredDefinition":"Text terms to capture the contents of eligibility exclusion criteria questions for Lombardi Cancer Center, IRB #03058, amendment 1, clinical trial.","longName":"ELIG_EXC_03058_01_NM","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"1. Does patient have a clinically active brain metastasis or an uncontrolled seizure disorder?","valueDescription":"1. Does patient have a clinically active brain metastasis or an uncontrolled seizure disorder?","ValueMeaning":{"publicId":"2580375","version":"1","preferredName":"1. Does patient have a clinically active brain metastasis or an uncontrolled seizure disorder?","longName":"2580375","preferredDefinition":"1. Does patient have a clinically active brain metastasis or an uncontrolled seizure disorder?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0704-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E0C55B-9FB0-4932-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"3. Has patient undergone recent major surgery (within 21 days)?","valueDescription":"3. Has patient undergone recent major surgery (within 21 days)?","ValueMeaning":{"publicId":"2580377","version":"1","preferredName":"3. Has patient undergone recent major surgery (within 21 days)?","longName":"2580377","preferredDefinition":"3. Has patient undergone recent major surgery (within 21 days)?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0706-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E0C55B-9FC8-4932-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"4. Does patient have any systemic anticancer treatment of kind within 30 days prior to initiating study medications?","valueDescription":"4. Does patient have any systemic anticancer treatment of kind within 30 days prior to initiating study medications?","ValueMeaning":{"publicId":"2580378","version":"1","preferredName":"4. Does patient have any systemic anticancer treatment of kind within 30 days prior to initiating study medications?","longName":"2580378","preferredDefinition":"4. Does patient have any systemic anticancer treatment of kind within 30 days prior to initiating study medications?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0707-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E0C55B-9FD4-4932-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"5. Have systemic vitamin A in doses exceeded 15,000 IU/day within 14 days prior to initiating study medication?","valueDescription":"5. Have systemic vitamin A in doses exceeded 15,000 IU/day within 14 days prior to initiating study medication?","ValueMeaning":{"publicId":"2580379","version":"1","preferredName":"5. Have systemic vitamin A in doses exceeded 15,000 IU/day within 14 days prior to initiating study medication?","longName":"2580379","preferredDefinition":"5. Have systemic vitamin A in doses exceeded 15,000 IU/day within 14 days prior to initiating study medication?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0708-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E0C55B-9FE0-4932-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"6. Does patient have unwillingness or inability to minimize exposure to sunlight and artificial ultraviolet light while receiving Targretin capsules?","valueDescription":"6. Does patient have unwillingness or inability to minimize exposure to sunlight and artificial ultraviolet light while receiving Targretin capsules?","ValueMeaning":{"publicId":"2580380","version":"1","preferredName":"6. Does patient have unwillingness or inability to minimize exposure to sunlight and artificial ultraviolet light while receiving Targretin capsules?","longName":"2580380","preferredDefinition":"6. Does patient have unwillingness or inability to minimize exposure to sunlight and artificial ultraviolet light while receiving Targretin capsules?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0709-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E0C55B-9FEC-4932-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"7. Does patient have a poorly controlled psychiatric illness?","valueDescription":"7. Does patient have a poorly controlled psychiatric illness?","ValueMeaning":{"publicId":"2580381","version":"1","preferredName":"7. Does patient have a poorly controlled psychiatric illness?","longName":"2580381","preferredDefinition":"7. Does patient have a poorly controlled psychiatric illness?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-070A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E0C55B-9FF8-4932-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"8. Does patient have congestive heart failure not adequately controlled with medications?","valueDescription":"8. Does patient have congestive heart failure not adequately controlled with medications?","ValueMeaning":{"publicId":"2580382","version":"1","preferredName":"8. Does patient have congestive heart failure not adequately controlled with medications?","longName":"2580382","preferredDefinition":"8. Does patient have congestive heart failure not adequately controlled with medications?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-070B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E0C55B-A004-4932-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"10. Does patient have risk factor for pancreatitis, e.g., prior pancreatitis, uncontrolled phyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus?","valueDescription":"10. Does patient have risk factor for pancreatitis, e.g., prior pancreatitis, uncontrolled phyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus?","ValueMeaning":{"publicId":"2580384","version":"1","preferredName":"10. Does patient have risk factor for pancreatitis, e.g., prior pancreatitis, uncontrolled phyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus?","longName":"2580384","preferredDefinition":"10. Does patient have risk factor for pancreatitis, e.g., prior pancreatitis, uncontrolled phyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-070D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E0C55B-A01C-4932-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"11. Does patient have risk factor for pancreatitis, e.g., biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity?","valueDescription":"11. Does patient have risk factor for pancreatitis, e.g., biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity?","ValueMeaning":{"publicId":"2580385","version":"1","preferredName":"11. Does patient have risk factor for pancreatitis, e.g., biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity?","longName":"2580385","preferredDefinition":"11. Does patient have risk factor for pancreatitis, e.g., biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-070E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E0C55B-A028-4932-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"12. Does patient have known severe hypersensitivity to Taxotere or other drugs formulated with polysorbate 80?","valueDescription":"12. Does patient have known severe hypersensitivity to Taxotere or other drugs formulated with polysorbate 80?","ValueMeaning":{"publicId":"2580386","version":"1","preferredName":"12. Does patient have known severe hypersensitivity to Taxotere or other drugs formulated with polysorbate 80?","longName":"2580386","preferredDefinition":"12. Does patient have known severe hypersensitivity to Taxotere or other drugs formulated with polysorbate 80?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-070F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E0C55B-A034-4932-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"13. Does patient have known hypersensitivity to bexarotene or other component of Targretin capsules?","valueDescription":"13. Does patient have known hypersensitivity to bexarotene or other component of Targretin capsules?","ValueMeaning":{"publicId":"2580387","version":"1","preferredName":"13. Does patient have known hypersensitivity to bexarotene or other component of Targretin capsules?","longName":"2580387","preferredDefinition":"13. Does patient have known hypersensitivity to bexarotene or other component of Targretin capsules?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0710-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E0C55B-A040-4932-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"14. Was patient in treatment with a non-approved or investigational drug within 30 days before Day 1 of trial treatment?","valueDescription":"14. Was patient in treatment with a non-approved or investigational drug within 30 days before Day 1 of trial treatment?","ValueMeaning":{"publicId":"2580388","version":"1","preferredName":"14. Was patient in treatment with a non-approved or investigational drug within 30 days before Day 1 of trial treatment?","longName":"2580388","preferredDefinition":"14. Was patient in treatment with a non-approved or investigational drug within 30 days before Day 1 of trial treatment?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0711-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E0C55B-A04C-4932-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"15. Does patient have incomplete healing from previous oncologic or other major surgery?","valueDescription":"15. Does patient have incomplete healing from previous oncologic or other major surgery?","ValueMeaning":{"publicId":"2580389","version":"1","preferredName":"15. Does patient have incomplete healing from previous oncologic or other major surgery?","longName":"2580389","preferredDefinition":"15. Does patient have incomplete healing from previous oncologic or other major surgery?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0712-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E0C55B-A058-4932-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"9. Does patient have serious intercurrent medical illnesses (in investigator's opinion) that would impair their ability to give informed consent or unacceptably reduce the safety of the proposed treatment?","valueDescription":"9. Does patient have serious intercurrent medical illnesses (in investigator's opinion) that would impair their ability to give informed consent or unacceptably reduce the safety of the proposed treatment?","ValueMeaning":{"publicId":"2580383","version":"1","preferredName":"9. Does patient have serious intercurrent medical illnesses (in investigator's opinion) that would impair their ability to give informed consent or unacceptably reduce the safety of the proposed treatment?","longName":"2580383","preferredDefinition":"9. Does patient have serious intercurrent medical illnesses (in investigator's opinion) that would impair their ability to give informed consent or unacceptably reduce the safety of the proposed treatment?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-070C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"COOPERM","dateModified":"2020-03-05","changeDescription":"Removed special characters for MDR data migration. 3.5.20 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A1C6EDBC-4F4E-4EE3-E053-F662850A9E71","beginDate":"2006-07-31","endDate":null,"createdBy":"TSESU","dateCreated":"2020-03-26","modifiedBy":"ONEDATA","dateModified":"2020-03-26","deletedIndicator":"No"},{"value":"2. Are platinum naive patients in the phase II portion?","valueDescription":"2. Are platinum naive patients in the phase II portion?","ValueMeaning":{"publicId":"2580376","version":"1","preferredName":"2. Are platinum naive patients in the phase II portion?","longName":"2580376","preferredDefinition":"2. Are platinum naive patients in the phase II portion?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0705-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"COOPERM","dateModified":"2020-03-05","changeDescription":"Removed special characters for MDR data migration. 3.5.20 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A1D97EF5-2767-5263-E053-F662850AD7EC","beginDate":"2006-07-31","endDate":null,"createdBy":"TSESU","dateCreated":"2020-03-27","modifiedBy":"ONEDATA","dateModified":"2020-03-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2261898","version":"1","preferredName":"Text Name","preferredDefinition":"Text; the words of something written.:The words or language units by which a thing is known.","longName":"C25704:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBDEE8CB-7C8A-5E8A-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"ONEDATA","dateModified":"2005-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19E0BF0E-2700-482D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"TSESU","dateModified":"2020-03-27","changeDescription":"Removed special characters for MDR data migration. 3.26.20 smt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Exclusion Criteria","type":"Preferred Question Text","description":"Exclusion Criteria","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19E0E39C-CCA1-4BBB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":"Curated to support C3PR application.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}